bromodomain and PHD finger containing 3Genealiases: []
Q-omics provides the consensus-scored BRPF3 profile across patient tissues and cancer cell-line models. BRPF3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BRPF3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, BRPF3 RNA expression shows 21,090 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where BRPF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRPF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRPF3 survival associations across molecular data types. BRPF3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRPF3 RNA expression–survival associations across cancer types. High BRPF3 expression shows unfavorable associations in ACC, STAD and MESO, but favorable associations in KIRC, UCS and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BRPF3 RNA expression.
This table summarizes BRPF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BRPF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRPF3 shows lower tumor expression in COAD and higher tumor expression in LIHC, LUAD, HNSC, BRCA and CHOL. The COAD box plot shows higher BRPF3 RNA expression in normal versus tumor tissue (log2 FC = −0.866, t-test p < 0.001).
This table shows molecular features associated with BRPF3 in patient tissues and cancer cell lines. In patient samples, BRPF3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRPF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
